Ocugen (NASDAQ: OCGN) has given vaccine investors a roller0coaster ride over the past year or so. It started out by soaring more than 700% in a few days after saying it would co-commercialize Bharat Biotech's coronavirus vaccine candidate -- Covaxin -- in the U.S. But as the project met bumps along the road, so did the share price. Today, Ocugen still hasn't commercialized Covaxin in the U.S. And the stock has lost more than 50% year to date.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting